Continuous glucose monitoring is expanding beyond type 1 diabetes, offering detailed glycemic insights that may support earlier intervention in patients with type 2 diabetes.

BOSTON--(BUSINESS WIRE)--CyberSaint, the leader in cyber risk management, is pleased to announce its inclusion in the latest Gartner® report, "Innovation Insight: Cybersecurity Continuous Control ...

RegScale, the AI-powered continuous controls monitoring (CCM) platform, today announced it has been recognized with multiple 2026 cybersecurity industry awards as organizations increasingly prioritize ...

The MarketWatch News Department was not involved in the creation of this content. New capabilities introduce industry-leading AI accuracy, automate testing, and bring agentic control testing to ...

He said there are minor fire-related hot spots, but they are very limited. Read more at straitstimes.com. Read more at ...

New capabilities introduce industry-leading AI accuracy, automate testing, and bring agentic control testing to ArcherIRM users. PALO ALTO, Calif., March 23, 2026 /PRNewswire/ -- Trustero AI, the ...

Claims data reveal larger hemoglobin A1c decreases in people with type 2 diabetes who use continuous glucose monitoring and semaglutide compared with semaglutide alone. Study Design: Using US health ...